Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adefovir + lamivudine
- Development stage
- Phase 1
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Adefovir + lamivudine is a combination of two antiviral drugs used primarily for the treatment of chronic hepatitis B virus (HBV) infection, especially in cases where resistance to monotherapy has developed. Adefovir is an acyclic nucleotide analog of adenosine monophosphate that inhibits HBV DNA polymerase (reverse transcriptase) by competing with deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA[2][6]. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that acts as a synthetic nucleoside analogue, phosphorylated intracellularly to its active metabolite, which inhibits both HIV reverse transcriptase and HBV polymerase by causing premature termination of the viral DNA chain[3][4][5]. The combination provides additive anti-HBV activity and may be used when resistance to either agent alone occurs.
- Brand names
- EpivirEpivir HbvZeffixCimduoCombivirDelstrigoDovatoEpzicomKivexaSymfiTriumeqTrizivir
- Other names
- adefovir dipivoxil
02
Targets
HBV Pol (Hepatitis B virus polymerase)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on adefovir + lamivudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adefovir + lamivudine.